The main objective of this guidance is to provide scientific advice on public health principles and considerations for infection and prevention control of COVID-19 in migrant and refugee reception and detention centres in the European Union and European Economic Area (EU/EEA) and the United Kingdom (UK).
Since 31 December 2019 and as of 9 June 2020, 7 069 278 cases of COVID-19 have been reported worldwide, including 405 587 deaths. EU/EEA countries and the UK reported 1 444 710 cases (20% of all cases), including 169 207 deaths (42% of all deaths).
This core protocol for ECDC studies of VE against hospitalisation with SARI laboratory-confirmed with SARS-CoV-2 or with influenza, version 3.0, represents an update to the main elements for a multi-country hospital-based study of COVID-19 vaccine effectiveness in patients hospitalised with SARI, initially published as version 1.0 [5], updated to version 2.0 [6].
In this report, we present an update of the 2020 primary systematic review, to take into account more recent evidence on the efficacy, effectiveness and safety of newer and/or enhanced seasonal influenza vaccines for the prevention of laboratory-confirmed influenza in individuals aged 18 years and over.
This document provides guidance on diagnostic testing, molecular characterisation and metagenomic analysis for suspect cases of severe acute hepatitis of unknown aetiology.
The purpose of this document is to review the evidence of COVID-19 vaccine effectiveness and duration of immunity following vaccination in adolescents aged 12-17 years, and to outline interim public health considerations for the potential use of a booster dose in this group.
Since 31 December 2019 and as of 22 April 2020, approximately 2.5 million (2 524 812) cases of COVID-19 have been reported worldwide and 177 780 deaths. Of these, 988 241 cases were reported by EU/EEA countries and the UK, including 105 064 deaths.
This document outlines strategies and objectives for sustainable SARS-CoV-2 testing of populations to achieve specific public health objectives in various epidemiological situations. General population-wide testing, as well as targeted testing of individuals, or specific populations related to particular settings, are presented on the basis of country experiences and information collected from scientific literature.
The SARS-CoV-2 Omicron variant of concern (VOC) is rapidly replacing SARS-CoV-2 Delta in most European Union/European Economic Area (EU/EEA) countries, and is broadly following a west-to-east progression.
This core protocol for ECDC studies of vaccine effectiveness against hospitalisation with Severe Acute Respiratory Infection laboratory-confirmed with SARS-CoV-2 or with influenza, version 2.0, represents an update to the main elements for a multi-country hospital-based study of COVID-19 vaccine effectiveness in patients hospitalised with Severe Acute Respiratory Infection (SARI), already published as version 1.0.